Neurocrine (NBIX) Biosciences announced that its Phase 2 study evaluating the efficacy, safety and tolerability of investigational compound NBI-1070770 in adults with major depressive disorder did not meet the primary endpoint compared to placebo. NBI-1070770 was generally well tolerated. “While we are disappointed that NBI-1070770 did not meet the primary endpoint, there are aspects of the data that warrant further exploration. Our team will continue to analyze these results so we can determine appropriate next steps,” said Sanjay Keswani, M.D., Chief Medical Officer, Neurocrine Biosciences. “We are grateful to the patients, investigators and site staff who participated in this trial.”
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine price target raised to $179 from $171 at JPMorgan
- Neurocrine Biosciences’ Earnings Call Highlights Robust Growth
- Neurocrine Biosciences Completes Phase 2 Study on NBI-1070770 for Depression
- Neurocrine price target raised to $184 from $170 at Needham
- Neurocrine falls after DOJ sends Ingrezza investigative demand